Opinion|Videos|March 31, 2025
Biological Mechanisms of GIST Resistance and Tumor Heterogeneity
Experts discuss the biological mechanisms of resistance in gastrointestinal stromal tumors (GIST), differentiating between primary and secondary resistance, and explore how tumor heterogeneity evolves throughout treatment, with implications for long-term management and treatment strategies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s start with the fundamentals of resistance in GIST. Could you explain the biological mechanisms of resistance in GIST? Could you differentiate between primary and secondary resistance in GIST and explain how each impacts your treatment approach?
- How does tumor heterogeneity evolve throughout treatment course, and what implications does this have for long-term management?
Advertisement
Related to this article
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
Roswell Park Comprehensive Cancer Center investigators will deliver 21 presentations at the AHNS 12th International Conference on Head and Neck Cancer.
Pelareorep plus a checkpoint inhibitor earned FDA fast track designation for pretreated, inoperable, recurrent, or metastatic squamous cell anal carcinoma.
Older age independently predicted higher non-relapse mortality and inferior overall survival outcomes after PTCy-based unrelated donor transplant.
The IL-10–expressing anti-CD19 CAR T-cell therapy produced a 92.9% complete response rate and a 92.9% 1-year overall survival rate in high-risk relapsed/refractory DLBCL.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Two optimized CD33-directed CAR T-cell therapies generated complete remissions with incomplete count recovery in heavily pretreated relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
3
Five Under 5: Top Oncology Videos for the Week of 7/12
4
Subcutaneous Pembrolizumab Faces Scrutiny Over Convenience and Cost for Patients With Cancer
5